The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
The transaction marks a clear portfolio reshuffle for Indoco
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
It promises fewer injections for vision loss patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
